Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 135

1.

Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis.

Soare A, Györfi HA, Matei AE, Dees C, Rauber S, Wohlfahrt T, Chen CW, Ludolph I, Horch RE, Bäuerle T, von Hörsten S, Mihai C, Distler O, Ramming A, Schett G, Distler JHW.

Arthritis Rheumatol. 2020 Jan;72(1):137-149. doi: 10.1002/art.41058.

PMID:
31350829
2.

Acyltransferase skinny hedgehog regulates TGFβ-dependent fibroblast activation in SSc.

Liang R, Kagwiria R, Zehender A, Dees C, Bergmann C, Ramming A, Krasowska D, Michalska-Jakubus M, Kreuter A, Kraner ME, Schett G, Distler JHW.

Ann Rheum Dis. 2019 Sep;78(9):1269-1273. doi: 10.1136/annrheumdis-2019-215066. Epub 2019 Jun 8.

PMID:
31177096
3.

PU.1 controls fibroblast polarization and tissue fibrosis.

Wohlfahrt T, Rauber S, Uebe S, Luber M, Soare A, Ekici A, Weber S, Matei AE, Chen CW, Maier C, Karouzakis E, Kiener HP, Pachera E, Dees C, Beyer C, Daniel C, Gelse K, Kremer AE, Naschberger E, Stürzl M, Butter F, Sticherling M, Finotto S, Kreuter A, Kaplan MH, Jüngel A, Gay S, Nutt SL, Boykin DW, Poon GMK, Distler O, Schett G, Distler JHW, Ramming A.

Nature. 2019 Feb;566(7744):344-349. doi: 10.1038/s41586-019-0896-x. Epub 2019 Jan 30.

4.

The tyrosine phosphatase SHP2 controls TGFβ-induced STAT3 signaling to regulate fibroblast activation and fibrosis.

Zehender A, Huang J, Györfi AH, Matei AE, Trinh-Minh T, Xu X, Li YN, Chen CW, Lin J, Dees C, Beyer C, Gelse K, Zhang ZY, Bergmann C, Ramming A, Birchmeier W, Distler O, Schett G, Distler JHW.

Nat Commun. 2018 Aug 14;9(1):3259. doi: 10.1038/s41467-018-05768-3.

5.

Poly(ADP-ribose) polymerase-1 regulates fibroblast activation in systemic sclerosis.

Zhang Y, Pötter S, Chen CW, Liang R, Gelse K, Ludolph I, Horch RE, Distler O, Schett G, Distler JHW, Dees C.

Ann Rheum Dis. 2018 May;77(5):744-751. doi: 10.1136/annrheumdis-2017-212265. Epub 2018 Feb 3.

PMID:
29431122
6.

Protein kinases G are essential downstream mediators of the antifibrotic effects of sGC stimulators.

Matei AE, Beyer C, Györfi AH, Soare A, Chen CW, Dees C, Bergmann C, Ramming A, Friebe A, Hofmann F, Distler O, Schett G, Distler JHW.

Ann Rheum Dis. 2018 Mar;77(3):459. doi: 10.1136/annrheumdis-2017-212489. Epub 2018 Jan 8.

PMID:
29311148
7.

The histone demethylase Jumonji domain-containing protein 3 (JMJD3) regulates fibroblast activation in systemic sclerosis.

Bergmann C, Brandt A, Merlevede B, Hallenberger L, Dees C, Wohlfahrt T, Pötter S, Zhang Y, Chen CW, Mallano T, Liang R, Kagwiria R, Kreuter A, Pantelaki I, Bozec A, Abraham D, Rieker R, Ramming A, Distler O, Schett G, Distler JHW.

Ann Rheum Dis. 2018 Jan;77(1):150-158. doi: 10.1136/annrheumdis-2017-211501. Epub 2017 Oct 25.

PMID:
29070530
8.

Oxidant sensor in the cGMP-binding pocket of PKGIα regulates nitroxyl-mediated kinase activity.

Donzelli S, Goetz M, Schmidt K, Wolters M, Stathopoulou K, Diering S, Prysyazhna O, Polat V, Scotcher J, Dees C, Subramanian H, Butt E, Kamynina A, Schobesberger S, King SB, Nikolaev VO, de Wit C, Leichert LI, Feil R, Eaton P, Cuello F.

Sci Rep. 2017 Aug 30;7(1):9938. doi: 10.1038/s41598-017-09275-1.

9.

Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis.

Huang J, Maier C, Zhang Y, Soare A, Dees C, Beyer C, Harre U, Chen CW, Distler O, Schett G, Wollin L, Distler JHW.

Ann Rheum Dis. 2017 Nov;76(11):1941-1948. doi: 10.1136/annrheumdis-2016-210823. Epub 2017 Aug 16.

PMID:
28814429
10.

Cannula-associated Ocular Injuries during Cataract Surgery: A Preventable Intraoperative Complication?

Ting DSJ, Dees C, Ellerton C.

Middle East Afr J Ophthalmol. 2017 Jan-Mar;24(1):54-56. doi: 10.4103/meajo.MEAJO_208_15.

11.

JAK1-dependent transphosphorylation of JAK2 limits the antifibrotic effects of selective JAK2 inhibitors on long-term treatment.

Zhang Y, Liang R, Chen CW, Mallano T, Dees C, Distler A, Reich A, Bergmann C, Ramming A, Gelse K, Mielenz D, Distler O, Schett G, Distler JHW.

Ann Rheum Dis. 2017 Aug;76(8):1467-1475. doi: 10.1136/annrheumdis-2016-210911. Epub 2017 May 6.

PMID:
28478401
12.

The transcription factor GLI2 as a downstream mediator of transforming growth factor-β-induced fibroblast activation in SSc.

Liang R, Šumová B, Cordazzo C, Mallano T, Zhang Y, Wohlfahrt T, Dees C, Ramming A, Krasowska D, Michalska-Jakubus M, Distler O, Schett G, Šenolt L, Distler JH.

Ann Rheum Dis. 2017 Apr;76(4):756-764. doi: 10.1136/annrheumdis-2016-209698. Epub 2016 Oct 28.

PMID:
27793816
13.

Composition of TWIST1 dimers regulates fibroblast activation and tissue fibrosis.

Palumbo-Zerr K, Soare A, Zerr P, Liebl A, Mancuso R, Tomcik M, Sumova B, Dees C, Chen CW, Wohlfahrt T, Mallano T, Distler A, Ramming A, Gelse K, Mihai C, Distler O, Schett G, Distler JH.

Ann Rheum Dis. 2017 Jan;76(1):244-251. doi: 10.1136/annrheumdis-2015-208470. Epub 2016 Apr 25.

PMID:
27113414
14.

Inhibition of Notch1 promotes hedgehog signalling in a HES1-dependent manner in chondrocytes and exacerbates experimental osteoarthritis.

Lin NY, Distler A, Beyer C, Philipi-Schöbinger A, Breda S, Dees C, Stock M, Tomcik M, Niemeier A, Dell'Accio F, Gelse K, Mattson MP, Schett G, Distler JH.

Ann Rheum Dis. 2016 Nov;75(11):2037-2044. doi: 10.1136/annrheumdis-2015-208420. Epub 2016 Feb 5.

PMID:
26851274
15.

Type 2 innate lymphoid cell counts are increased in patients with systemic sclerosis and correlate with the extent of fibrosis.

Wohlfahrt T, Usherenko S, Englbrecht M, Dees C, Weber S, Beyer C, Gelse K, Distler O, Schett G, Distler JH, Ramming A.

Ann Rheum Dis. 2016 Mar;75(3):623-6. doi: 10.1136/annrheumdis-2015-207388. Epub 2015 Sep 2.

PMID:
26338035
16.

From pathogenesis to therapy--Perspective on treatment strategies in fibrotic diseases.

Ramming A, Dees C, Distler JH.

Pharmacol Res. 2015 Oct;100:93-100. doi: 10.1016/j.phrs.2015.06.012. Epub 2015 Jul 16.

PMID:
26188266
17.

Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies.

Dees C, Beyer C, Distler A, Soare A, Zhang Y, Palumbo-Zerr K, Distler O, Schett G, Sandner P, Distler JH.

Ann Rheum Dis. 2015 Aug;74(8):1621-5. doi: 10.1136/annrheumdis-2014-206809. Epub 2015 Mar 27.

PMID:
25817717
18.

Tribbles homologue 3 stimulates canonical TGF-β signalling to regulate fibroblast activation and tissue fibrosis.

Tomcik M, Palumbo-Zerr K, Zerr P, Sumova B, Avouac J, Dees C, Distler A, Becvar R, Distler O, Schett G, Senolt L, Distler JH.

Ann Rheum Dis. 2016 Mar;75(3):609-16. doi: 10.1136/annrheumdis-2014-206234. Epub 2015 Jan 20.

PMID:
25603829
19.

Activating transcription factor 3 regulates canonical TGFβ signalling in systemic sclerosis.

Mallano T, Palumbo-Zerr K, Zerr P, Ramming A, Zeller B, Beyer C, Dees C, Huang J, Hai T, Distler O, Schett G, Distler JH.

Ann Rheum Dis. 2016 Mar;75(3):586-92. doi: 10.1136/annrheumdis-2014-206214. Epub 2015 Jan 14.

PMID:
25589515
20.

Orphan nuclear receptor NR4A1 regulates transforming growth factor-β signaling and fibrosis.

Palumbo-Zerr K, Zerr P, Distler A, Fliehr J, Mancuso R, Huang J, Mielenz D, Tomcik M, Fürnrohr BG, Scholtysek C, Dees C, Beyer C, Krönke G, Metzger D, Distler O, Schett G, Distler JH.

Nat Med. 2015 Feb;21(2):150-8. doi: 10.1038/nm.3777. Epub 2015 Jan 12.

PMID:
25581517
21.

Cardiomyopathy in murine models of systemic sclerosis.

Venalis P, Kumánovics G, Schulze-Koops H, Distler A, Dees C, Zerr P, Palumbo-Zerr K, Czirják L, Mackevic Z, Lundberg IE, Distler O, Schett G, Distler JH.

Arthritis Rheumatol. 2015 Feb;67(2):508-16. doi: 10.1002/art.38942.

22.

The nuclear receptor constitutive androstane receptor/NR1I3 enhances the profibrotic effects of transforming growth factor β and contributes to the development of experimental dermal fibrosis.

Avouac J, Palumbo-Zerr K, Ruzehaji N, Tomcik M, Zerr P, Dees C, Distler A, Beyer C, Schneider H, Distler O, Schett G, Allanore Y, Distler JH.

Arthritis Rheumatol. 2014 Nov;66(11):3140-50. doi: 10.1002/art.38819.

23.

S100A4 amplifies TGF-β-induced fibroblast activation in systemic sclerosis.

Tomcik M, Palumbo-Zerr K, Zerr P, Avouac J, Dees C, Sumova B, Distler A, Beyer C, Cerezo LA, Becvar R, Distler O, Grigorian M, Schett G, Senolt L, Distler JH.

Ann Rheum Dis. 2015 Sep;74(9):1748-55. doi: 10.1136/annrheumdis-2013-204516. Epub 2014 Apr 7.

PMID:
24709861
24.

Activation of liver X receptors inhibits experimental fibrosis by interfering with interleukin-6 release from macrophages.

Beyer C, Huang J, Beer J, Zhang Y, Palumbo-Zerr K, Zerr P, Distler A, Dees C, Maier C, Munoz L, Krönke G, Uderhardt S, Distler O, Jones S, Rose-John S, Oravecz T, Schett G, Distler JH.

Ann Rheum Dis. 2015 Jun;74(6):1317-24. doi: 10.1136/annrheumdis-2013-204401. Epub 2014 Mar 11.

PMID:
24618263
25.

Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGFβ signalling.

Beyer C, Zenzmaier C, Palumbo-Zerr K, Mancuso R, Distler A, Dees C, Zerr P, Huang J, Maier C, Pachowsky ML, Friebe A, Sandner P, Distler O, Schett G, Berger P, Distler JH.

Ann Rheum Dis. 2015 Jul;74(7):1408-16. doi: 10.1136/annrheumdis-2013-204508. Epub 2014 Feb 23.

PMID:
24567525
26.

Vitamin D receptor regulates TGF-β signalling in systemic sclerosis.

Zerr P, Vollath S, Palumbo-Zerr K, Tomcik M, Huang J, Distler A, Beyer C, Dees C, Gela K, Distler O, Schett G, Distler JH.

Ann Rheum Dis. 2015 Mar;74(3):e20. doi: 10.1136/annrheumdis-2013-204378. Epub 2014 Jan 21.

PMID:
24448349
27.

Inhibition of casein kinase II reduces TGFβ induced fibroblast activation and ameliorates experimental fibrosis.

Zhang Y, Dees C, Beyer C, Lin NY, Distler A, Zerr P, Palumbo K, Susok L, Kreuter A, Distler O, Schett G, Distler JH.

Ann Rheum Dis. 2015 May;74(5):936-43. doi: 10.1136/annrheumdis-2013-204256. Epub 2014 Jan 15.

PMID:
24431397
28.

Inactivation of evenness interrupted (EVI) reduces experimental fibrosis by combined inhibition of canonical and non-canonical Wnt signalling.

Distler A, Ziemer C, Beyer C, Lin NY, Chen CW, Palumbo-Zerr K, Dees C, Weidemann A, Distler O, Schett G, Distler JH.

Ann Rheum Dis. 2014 Mar;73(3):624-7. doi: 10.1136/annrheumdis-2013-203995. Epub 2013 Nov 20.

PMID:
24257024
29.

Canonical Wnt signalling as a key regulator of fibrogenesis - implications for targeted therapies?

Dees C, Distler JH.

Exp Dermatol. 2013 Nov;22(11):710-3. doi: 10.1111/exd.12255. Review.

PMID:
24118232
30.

Levels of target activation predict antifibrotic responses to tyrosine kinase inhibitors.

Maurer B, Distler A, Dees C, Khan K, Denton CP, Abraham D, Gay RE, Michel BA, Gay S, Hw Distler J, Distler O.

Ann Rheum Dis. 2013 Dec;72(12):2039-46. doi: 10.1136/annrheumdis-2013-203729. Epub 2013 Sep 7.

PMID:
24013728
31.

The Wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosis.

Dees C, Schlottmann I, Funke R, Distler A, Palumbo-Zerr K, Zerr P, Lin NY, Beyer C, Distler O, Schett G, Distler JH.

Ann Rheum Dis. 2014 Jun;73(6):1232-9. doi: 10.1136/annrheumdis-2012-203194. Epub 2013 May 22.

PMID:
23698475
32.

Blockade of canonical Wnt signalling ameliorates experimental dermal fibrosis.

Beyer C, Reichert H, Akan H, Mallano T, Schramm A, Dees C, Palumbo-Zerr K, Lin NY, Distler A, Gelse K, Varga J, Distler O, Schett G, Distler JH.

Ann Rheum Dis. 2013 Jul;72(7):1255-8. doi: 10.1136/annrheumdis-2012-202544. Epub 2013 Apr 17.

PMID:
23595143
33.

Activation of pregnane X receptor inhibits experimental dermal fibrosis.

Beyer C, Skapenko A, Distler A, Dees C, Reichert H, Munoz L, Leipe J, Schulze-Koops H, Distler O, Schett G, Distler JH.

Ann Rheum Dis. 2013 Apr;72(4):621-5. doi: 10.1136/annrheumdis-2012-202476. Epub 2013 Jan 4.

PMID:
23291432
34.

Morphogen pathways as molecular targets for the treatment of fibrosis in systemic sclerosis.

Beyer C, Dees C, Distler JH.

Arch Dermatol Res. 2013 Jan;305(1):1-8. doi: 10.1007/s00403-012-1304-7. Epub 2012 Dec 4. Review.

PMID:
23208311
35.

Inactivation of tankyrases reduces experimental fibrosis by inhibiting canonical Wnt signalling.

Distler A, Deloch L, Huang J, Dees C, Lin NY, Palumbo-Zerr K, Beyer C, Weidemann A, Distler O, Schett G, Distler JH.

Ann Rheum Dis. 2013 Sep 1;72(9):1575-80. doi: 10.1136/annrheumdis-2012-202275. Epub 2012 Nov 12.

PMID:
23148305
36.

Autophagy regulates TNFα-mediated joint destruction in experimental arthritis.

Lin NY, Beyer C, Giessl A, Kireva T, Scholtysek C, Uderhardt S, Munoz LE, Dees C, Distler A, Wirtz S, Krönke G, Spencer B, Distler O, Schett G, Distler JH.

Ann Rheum Dis. 2013 May;72(5):761-8. doi: 10.1136/annrheumdis-2012-201671. Epub 2012 Sep 12.

PMID:
22975756
37.

Combined inhibition of c-Abl and PDGF receptors for prevention and treatment of murine sclerodermatous chronic graft-versus-host disease.

Zerr P, Distler A, Palumbo-Zerr K, Tomcik M, Vollath S, Dees C, Egberts F, Tinazzi I, Del Galdo F, Distler O, Schett G, Spriewald BM, Distler JH.

Am J Pathol. 2012 Nov;181(5):1672-80. doi: 10.1016/j.ajpath.2012.07.017. Epub 2012 Aug 31.

PMID:
22940072
38.

Inhibition of hedgehog signaling for the treatment of murine sclerodermatous chronic graft-versus-host disease.

Zerr P, Palumbo-Zerr K, Distler A, Tomcik M, Vollath S, Munoz LE, Beyer C, Dees C, Egberts F, Tinazzi I, Del Galdo F, Distler O, Schett G, Spriewald BM, Distler JH.

Blood. 2012 Oct 4;120(14):2909-17. doi: 10.1182/blood-2012-01-403428. Epub 2012 Aug 22.

39.

Inhibition of H3K27 histone trimethylation activates fibroblasts and induces fibrosis.

Krämer M, Dees C, Huang J, Schlottmann I, Palumbo-Zerr K, Zerr P, Gelse K, Beyer C, Distler A, Marquez VE, Distler O, Schett G, Distler JH.

Ann Rheum Dis. 2013 Apr;72(4):614-20. doi: 10.1136/annrheumdis-2012-201615. Epub 2012 Aug 21.

PMID:
22915621
40.

Inactivation of fatty acid amide hydrolase exacerbates experimental fibrosis by enhanced endocannabinoid-mediated activation of CB1.

Palumbo-Zerr K, Horn A, Distler A, Zerr P, Dees C, Beyer C, Selvi E, Cravatt BF, Distler O, Schett G, Distler JH.

Ann Rheum Dis. 2012 Dec;71(12):2051-4. doi: 10.1136/annrheumdis-2012-201823. Epub 2012 Aug 22.

PMID:
22915616
41.

Inhibition of sumoylation prevents experimental fibrosis.

Khodzhigorova A, Distler A, Lang V, Dees C, Schneider H, Beyer C, Gelse K, Distler O, Schett G, Distler JH.

Ann Rheum Dis. 2012 Nov;71(11):1904-8. doi: 10.1136/annrheumdis-2012-201746. Epub 2012 Aug 17. Erratum in: Ann Rheum Dis. 2013 Jun;72(6):1110.

PMID:
22904261
42.

Pomalidomide is effective for prevention and treatment of experimental skin fibrosis.

Weingärtner S, Zerr P, Tomcik M, Palumbo-Zerr K, Distler A, Dees C, Beyer C, Shankar SL, Cedzik D, Schafer PH, Distler O, Schett G, Distler JH.

Ann Rheum Dis. 2012 Nov;71(11):1895-9. doi: 10.1136/annrheumdis-2012-201784. Epub 2012 Aug 17.

PMID:
22904257
43.

JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor β in systemic sclerosis.

Dees C, Tomcik M, Palumbo-Zerr K, Distler A, Beyer C, Lang V, Horn A, Zerr P, Zwerina J, Gelse K, Distler O, Schett G, Distler JH.

Arthritis Rheum. 2012 Sep;64(9):3006-15. doi: 10.1002/art.34500.

44.

Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis.

Akhmetshina A, Palumbo K, Dees C, Bergmann C, Venalis P, Zerr P, Horn A, Kireva T, Beyer C, Zwerina J, Schneider H, Sadowski A, Riener MO, MacDougald OA, Distler O, Schett G, Distler JH.

Nat Commun. 2012 Mar 13;3:735. doi: 10.1038/ncomms1734.

45.

Inhibition of hedgehog signalling prevents experimental fibrosis and induces regression of established fibrosis.

Horn A, Kireva T, Palumbo-Zerr K, Dees C, Tomcik M, Cordazzo C, Zerr P, Akhmetshina A, Ruat M, Distler O, Beyer C, Schett G, Distler JH.

Ann Rheum Dis. 2012 May;71(5):785-9. doi: 10.1136/annrheumdis-2011-200883. Epub 2012 Mar 8.

PMID:
22402139
46.

Hedgehog signaling controls fibroblast activation and tissue fibrosis in systemic sclerosis.

Horn A, Palumbo K, Cordazzo C, Dees C, Akhmetshina A, Tomcik M, Zerr P, Avouac J, Gusinde J, Zwerina J, Roudaut H, Traiffort E, Ruat M, Distler O, Schett G, Distler JH.

Arthritis Rheum. 2012 Aug;64(8):2724-33. doi: 10.1002/art.34444.

47.

β-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis.

Beyer C, Schramm A, Akhmetshina A, Dees C, Kireva T, Gelse K, Sonnylal S, de Crombrugghe B, Taketo MM, Distler O, Schett G, Distler JH.

Ann Rheum Dis. 2012 May;71(5):761-7. doi: 10.1136/annrheumdis-2011-200568. Epub 2012 Feb 10.

48.

Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis.

Beyer C, Reich N, Schindler SC, Akhmetshina A, Dees C, Tomcik M, Hirth-Dietrich C, von Degenfeld G, Sandner P, Distler O, Schett G, Distler JH.

Ann Rheum Dis. 2012 Jun;71(6):1019-26. doi: 10.1136/annrheumdis-2011-200862. Epub 2012 Jan 30.

PMID:
22294631
49.

The 12/15-lipoxygenase pathway counteracts fibroblast activation and experimental fibrosis.

Krönke G, Reich N, Scholtysek C, Akhmetshina A, Uderhardt S, Zerr P, Palumbo K, Lang V, Dees C, Distler O, Schett G, Distler JH.

Ann Rheum Dis. 2012 Jun;71(6):1081-7. doi: 10.1136/annrheumdis-2011-200745. Epub 2012 Jan 20.

PMID:
22267335
50.

Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis.

Reich N, Tomcik M, Zerr P, Lang V, Dees C, Avouac J, Palumbo K, Horn A, Akhmetshina A, Beyer C, Xie W, Bennett BL, Distler O, Schett G, Distler JH.

Ann Rheum Dis. 2012 May;71(5):737-45. doi: 10.1136/annrheumdis-2011-200412. Epub 2012 Jan 18.

PMID:
22258492

Supplemental Content

Support Center